approval · primary record
OCRELIZUMAB AND HYALURONIDASE-OCSQ
FDA · BLA · 2026-06-17
| Agency | FDA |
|---|---|
| Submission type | BLA |
| Latest action | 2026-06-17 |
| Approval events | 1 |
| Brand | OCREVUS ZUNOVO |
| Sponsor | GENENTECH INC |
| Route | INJECTION |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-06-17 | FDA | BLA | OCREVUS ZUNOVO | GENENTECH INC | INJECTION |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:10.874Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:ocrelizumab-and-hyaluronidase-ocsq
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ocrelizumab And Hyaluronidase-Ocsq · compound